Matinas BioPharma
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
March 27, 2024 16:05 ET | Matinas BioPharma Holdings, Inc.
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded...
TysonFoodsInc_Logo_Feb28.png
Tyson Foods Announces Second Quarter Earnings Conference Call and Webcast
March 27, 2024 16:05 ET | Tyson Foods, Inc.
SPRINGDALE, Ark., March 27, 2024 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) will release second quarter 2024 financial results on Monday, May 6, 2024. Management will host a conference call...
Mereo-Logo-(full-colour)-RGB.jpg
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET | Mereo BioPharma Group plc
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively ...
TXT.png
Top 10 Split Trust Announces Year End Results
March 27, 2024 16:01 ET | Top 10 Split Trust
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) --  (TSX: TXT.UN; TXT.PR.A) Top 10 Split Trust (the “Fund”) announces results of operations for the year ended December 31, 2023. Increase in net assets...
MPY LOGO (002).PNG
Mulvihill Premium Yield Fund Announces Year End Results
March 27, 2024 16:01 ET | Mulvihill Premium Yield
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Mulvihill Premium Yield Fund (the “Fund”) (TSX: MPY) announces results of operations for the year ended December 31, 2023. Decrease in net assets...
MulkvihilUSHelathcare.png
Mulvihill U.S. Health Care Enhanced Yield ETF Announces Year End Results
March 27, 2024 16:01 ET | Mulvihill U.S. Health Care Enhanced Yield ETF
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- (TSX: XLVE) Mulvihill U.S. Health Care Enhanced Yield ETF (the “Fund”) announces results of operations for the year ended December 31, 2023. Decrease in...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
March 27, 2024 16:01 ET | Praxis Precision Medicines, Inc.
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
mETF-CBNK_Lockup.png
Mulvihill Canadian Bank Enhanced Yield ETF Announces Year End Results
March 27, 2024 16:01 ET | Mulvihill Canadian Bank Enhanced Yield ETF
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF (the “Fund”) announces results of operations for the year ended December 31, 2023. Increase in net...
Avalo-Final_Black-01.jpg
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024 16:01 ET | Avalo Therapeutics
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private...
STRATA Skin Sciences Logo.jpg
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
March 27, 2024 16:01 ET | STRATA Skin Sciences, Inc.
HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and...